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Abstract
Background: Compared with other common plant foods, walnuts (Juglans regia) are consistently ranked among the 
highest in antioxidant capacity. In vitro, walnut polyphenols inhibit plasma and LDL oxidation, while in animal models 
they lower biomarkers of oxidative stress and raise antioxidant capacity. A limited number of human feeding trials 
indicate that walnuts improve some measures of antioxidant status, but not others.
Methods: A 19 wk, randomized crossover trial was conducted in 21 generally healthy men and postmenopausal 
women ≥50 y to study the dose-response effects of walnut intake on biomarkers of antioxidant activity, oxidative 
stress, and nutrient status. Subjects were randomized to receive either 21 or 42 g raw walnuts/d during each 6 wk 
intervention phase with a 6 wk washout between phases. Subjects were instructed to consume their usual diet, but 
refrain from eating any other tree nuts, seeds, peanuts, or ellagitannin-rich foods during the entire study, and other 
polyphenol-rich foods for 2 d prior to each study visit.
Results: Compared to baseline levels, red blood cell (RBC) linoleic acid and plasma pyridoxal phosphate (PLP) were 
significantly higher after 6 wk with 42 g/d walnuts (P < 0.05 for both). Overall, changes in plasma total thiols, and other 
antioxidant biomarkers, were not significant with either walnut dose. However, when compared to fasting levels, 
plasma total thiols were elevated within 1 h of walnut consumption with both doses during the baseline and end visits 
for each intervention phase (P < 0.05 for all). Despite the observed increase in RBC linoleic and linolenic acids 
associated with walnut consumption, this substrate for lipid peroxidation only minimally affected malondialdehyde 
(MDA) and antioxidant capacity. The proportional changes in MDA and Oxygen Radical Absorbance Capacity (ORAC) 
were consistent with a dose-response effect, although no significant within- or between-group differences were 
observed for these measures.
Conclusions: Walnut consumption did not significantly change the plasma antioxidant capacity of healthy, well-
nourished older adults in this pilot study. However, improvements in linoleic acid and pyridoxal phosphate were 
observed with chronic consumption, while total plasma thiols were enhanced acutely. Future studies investigating the 
antioxidant effects of walnuts in humans are warranted, but should include either a larger sample size or a controlled 
feeding intervention.
Trial Registration: ClinicalTrials.gov: NCT00626691
Background
Epidemiological studies consistently show that increased
consumption of plant-based, antioxidant-rich foods, i.e.,
fruits, vegetables, whole grains, and nuts, is associated
with the reduced risk for several chronic diseases. Clini-
cal trials have demonstrated that a nut-containing diet
low in saturated fat and cholesterol, while high in poly-
and monounsaturated fatty acids, has a beneficial effect
on plasma lipids and lipoproteins when compared with
either a low fat or average American diet [1]. However,
the LDL cholesterol-lowering response shown in these
trials is greater than expected based on equations derived
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Page 2 of 10from dietary fatty acid profiles, and may not be solely due
to the fatty acid composition of nuts [2]. Other bioactive
compounds present in nuts, including micronutrients,
fiber, and phytochemicals, may also contribute to their
cardio-protective effect by reducing inflammation,
improving vascular reactivity, and lowering oxidative
stress [2].
Among common plant foods consumed worldwide,
walnuts (Juglans regia) were ranked second only to rose
hips (Rosa canina) in their antioxidant activity, as deter-
mined by the ferric reducing antioxidant power (FRAP)
assay [3]. Compared with other tree nuts, walnuts were
also ranked highest when measured with the FRAP, total
radical-trapping antioxidant parameter (TRAP), and
Trolox equivalent antioxidant capacity (TEAC) assays [4].
Most of this antioxidant activity can be attributed to the
polyphenolic constituents, including the ellagitannins,
present primarily in the pellicle [5].
Polyphenols isolated from walnuts, including ellagic
acid monomers, polymeric tannins, and other phenolic
compounds, are potent inhibitors of plasma and LDL oxi-
dation in vitro [6], and have been found to decrease bio-
markers of oxidative stress in diabetic mice [7].
Melatonin, another antioxidant constituent present in
walnuts, has been positively correlated with increased
plasma antioxidant capacity in rats [8]. A limited number
of human feeding trials, conducted in subjects at high
risk for CVD, indicate that walnuts improve endothelial
function [9], and affect some measures of antioxidant sta-
tus [10], but not others [11].
The goal of this pilot study was to determine whether
consuming walnuts in amounts readily incorporated into
the diet can affect the plasma antioxidant capacity and
nutrient status of healthy older adults in a dose-depen-
dent manner. There are many different kinds of antioxi-
dants differentially distributed in blood, such that each
assay currently available quantifies the overall contribu-
tion of each antioxidant in a different way [12]. Thus,
employing a panel of established assays should more
accurately quantify the overall antioxidant response to a
walnut intervention.
Methods
Study Design and Intervention
A 19 wk, randomized crossover trial was conducted in 21
generally healthy men and postmenopausal women ≥50 y
to study the dose-response effects of chronic walnut
intake on biomarkers of antioxidant activity, oxidative
stress, and nutrient status. Subjects were asked to refrain
from eating any other tree nuts, seeds, peanuts, or ellagi-
tannin-rich foods (including berries, wine, cocoa, tea, and
pomegranates) during the entire 19 wk study, and other
polyphenol-rich foods (including most fruits, vegetables,
beans, legumes, whole grains, olive oil and coffee) for 2 d
prior to each study visit. The trial consisted of a 1 wk run-
in period, two 6 wk intervention phases, and a 6 wk wash-
out period between interventions. Subjects were ran-
domized to receive either 21 or 42 g packaged raw
walnuts/d during the first intervention phase and the
alternate dose during the second intervention phase. The
doses were based on the FDA qualified health claim that
the regular consumption of 1.50 oz (42 g)/d walnuts
decreases the risk of heart disease. Packaged walnuts
were provided by the California Walnut Commission
(Folsom, CA). Fasting plasma samples were collected at
the baseline and end of each 6 wk phase. Plasma samples
were also collected 1 h post-walnut consumption
(included in a standard meal) at each of these visits. Ran-
domization was stratified by gender according to a com-
puter generated list. Study personnel were blinded to the
treatment assignment for the duration of the intervention
and sample analysis. The only exception was the study
dietitian who was responsible for distributing the walnuts
and dietary instructions to eligible subjects at randomiza-
tion, and assessing compliance. During each visit, sub-
jects reported to the Jean Mayer USDA Human Nutrition
Research Center on Aging (HNRCA) at Tufts University
after fasting for 12 h. At each visit, subjects were queried
regarding interval changes in health, as well as use of pre-
scription medications, tobacco, and dietary supplements.
Subject eligibility
Twenty-one non-smoking men and postmenopausal
women, age ≥50 y, with body mass index (BMI) 18.5-35
kg/m2 were recruited from the greater Boston area via
newspaper advertisements, direct mailings, and clinic
postings. Subjects were excluded if they had a history or
known allergy to nuts of any kind; regularly consumed ≥5
oz (140 g) nuts/wk within 6 wk of study admission; were
taking estrogen, oral steroids or cholesterol-lowering
medications; had renal, endocrine or gastrointestinal dis-
ease, rheumatoid arthritis; presented with systolic blood
pressure >150 mm Hg and/or diastolic blood pressure
>95 mm Hg; had usual ethanol intake ≥2 drinks (28 g)/d
or used illicit drugs; presented with EKG or standard
clinical laboratory values outside acceptable parameters.
Subjects were also excluded if they used dietary supple-
ments containing either fish oils, high doses (≥3× U.S.
Daily Value) of vitamins C, E, β-carotene or selenium,
and/or phenolic compounds (e.g., herbal or berry-con-
taining preparations) within 6 wk of study admission.
In total, 23 volunteers were recruited for an initial base-
line screening visit between February and October 2007.
Two subjects declined to participate after the dietary
restrictions were reviewed, but before the start of the first
6 wk period. No subject dropped out of the study prior to
completion. The study design was approved by the Insti-
tutional Review Board of Tufts University Health Sci-
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signed a written informed consent agreement before par-
ticipating.
Sample Collection and Preparation
Collected samples were assessed for selected measures of
antioxidant activity (ORAC, ORAC with perchloric acid
(pca) precipitation, FRAP, and Total Antioxidant Perfor-
mance [TAP]), lipid peroxidation (MDA), biomarkers of
antioxidant status (total thiols, phenols, carotenoids, and
glutathione peroxidase [GPX]), micronutrients (α- and γ-
tocopherol, folate, pyridoxal phosphate, vitamin C, mag-
nesium), RBC fatty acid profiles, and lipid profile (total,
low density lipoprotein [LDL] and high density lipopro-
tein [HDL] cholesterol, and triglycerides) in fasting
plasma at the baseline and end of each walnut interven-
tion phase. Data were also collected on ORAC, ORAC-
pca, FRAP, total phenols, and thiols in plasma 1-h after
walnut consumption at each visit during the intervention.
Blood samples for the analysis of FRAP, TAP, MDA,
total thiols, phenols, fatty acids, lipids, folate, PLP, carote-
noids, and vitamins C and E were collected in EDTA-con-
taining evacuated tubes and centrifuged within 15 min of
drawing (3000 × g, 15 min, 4°C) with a SUR-Sep cap
(Organon Teknika, Durham, NC). Samples for the ORAC
and plasma glutathione peroxidase assays were collected
in heparin tubes, while samples for the analysis of magne-
sium were collected in trace metal-free tubes (Becton,
Dickinson, and Company, Franklin Lakes, NJ) and pro-
cessed similarly. Samples for MDA analysis were pre-
pared by adding 10 μL of 50 μM butylated
hydroxytoluene (BHT) to 250 μL of plasma. An equal vol-
ume of cold 0.35 M perchloric acid was mixed with the
plasma sample for vitamin C analysis, followed by centrif-
ugation (2500 × g, 10 min, 4°C). For the fatty acid analy-
ses, packed red blood cells (RBC) were washed with
saline and BHT added at 0.4 mg/mL to prevent oxidation.
Sample aliquots were stored in 2 mL NUNC tubes (Van-
guard Cryotubes, Neptune, NJ) at -80°C. Aliquots for the
magnesium analysis were stored in acid-washed storage
tubes also at -80°C. All samples for each subject were ana-
lyzed within the same run for every assay performed.
Biochemical Analyses
Antioxidant activity markers
The ORAC values of whole plasma and perchloric acid
treated protein-free plasma were determined according
to the method of Huang et al. [13] and Cao et al. [14]. The
assay was carried out on a FLUOstar OPTIMA plate
reader using a fluorescence filter with an excitation wave-
length of 485 nm and an emission wavelength of 520 nm
with the data expressed as μmol Trolox Equivalents (TE)/
L. The FRAP value of whole plasma was determined with
the spectrophotometric method of Benzie [15] with the
data expressed as μmol TE/L. Serum TAP was deter-
mined by the method developed by Aldini et al. [16] to
measure total antioxidant capacity in both the hydro-
philic and lipophilic compartments of serum, and vali-
dated by Beretta et al. [17] for the application to high
throughput studies. This method measures the rate of
oxidation of 4,4-difluoro-5-(4-phenyl-1,3-butadienyl)-4-
bora-3a,4a-diaza-s-indacene-3-undecanoic acid
(BODIPY 581/591), a lipid-soluble fluorescent probe, and
uses the lipid-soluble radical initiator 2,2'-azobis(4-meth-
oxy-2,4-dimethylvaleronitrile) (MeO-AMVN). Oxida-
tion is determined by monitoring the appearance of green
fluorescence of the oxidation product of BODIPY with an
excitation wavelength of 500 nm and emission wave-
length of 520 nm using a 1420 multilabel counter (Wallac
Victor 2, Perkin Elmer Life Sciences, MA). The results are
expressed as TAP values, which represent the percentage
of inhibition of BODIPY oxidation in human serum with
respect to that occurring in a control sample consisting of
BODIPY 581/591 in phosphatidylcholine liposomes.
Lipid peroxidation
Plasma MDA was measured by HPLC with fluorometric
detection [18] with the data expressed as μmol/L.
Antioxidant biomarkers
Total thiols in plasma were determined spectrophoto-
metrically according to Hu [19] and the data expressed as
mmol/L. The total phenol content of plasma was deter-
mined by the Folin-Ciocalteu reaction according to Sin-
gleton et al. [20] with the data expressed as μmol gallic
acid equivalents (GAE)/L. Total carotenoids were deter-
mined spectrophotometrically according to the method
described by Roels et al. [21]. GPX activity was assessed
using a kinetic assay with UV detection according to
Pleban et al. [22].
Plasma micronutrients
A reverse-phase gradient HPLC method was used for the
simultaneous determination of α- and γ-tocopherol [23].
PLP was measured with a radioenzymatic assay described
by Camp et at. [24]. Folic acid was assessed with a chemi-
luminescent immunoassay (Diagnostic Products Corpo-
ration, Los Angeles, CA). Vitamin C was measured with
an isocratic reverse-phase HPLC procedure according to
Behrens et al. [25]. Magnesium was determined with a
clinical chemistry analyzer (Olympus AU400, Center Val-
ley, PA) according to the manufacturers' instructions.
Fatty acids
RBC fatty acid profiles were quantified using an estab-
lished gas chromatography method as previously
described [26,27]. Peaks of interest were identified by
comparison with authentic fatty acid standards (Nu-
Check-Prep, Elysian, MN) and the data expressed as
molar percentage (mol %) proportions of fatty acids rela-
tive to the internal standard.
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Plasma concentrations of total cholesterol, LDL, HDL,
and triglycerides were determined with a clinical chemis-
try analyzer (Olympus AU400, Center Valley, PA) accord-
ing to the manufacturers' instructions.
Dietary Assessment
Dietary assessments were made at the baseline and end of
each 6 wk intervention phase using a validated food fre-
quency questionnaire (Fred Hutchinson Cancer Research
Center Food Frequency Questionnaire Version 06.10.88,
Cancer Prevention Research Program, Fred Hutchinson
Cancer Research Center, Seattle, WA) to determine usual
nutrient intakes and detect any significant changes that
may have occurred during the intervention periods.
Compliance
Compliance was measured by having each subject keep
track of their walnut intake using a daily diary chart, and
by having the study dietitian count opened bags at each
visit. Compliance with the walnut regimen was deter-
mined to be >90%.
Statistical analyses
Statistical analyses were performed using SPSS version
15.0 (SPSS, Inc., Chicago, IL). All outcome variables were
tested for sequence and dose effects using a linear mixed
model; none were found. Paired t-tests were used to com-
pare changes from baseline values for each respective
walnut dose at 1 h post-consumption and after 6 wk of
daily consumption, and to compare changes between the
two walnut doses achieved after each 6 wk intervention.
Regression was used to assess the independent predictive
capability of the plasma micronutrients on antioxidant
activity measures. Student's t test and chi-square analyses
were used to compare baseline characteristics between
the two groups at randomization. Unless otherwise
noted, results are expressed as either mean ± SD or %
change from baseline with respective P values for within
and between group differences. P values < 0.05 were con-
sidered statistically significant.
Results
The nutrient content of each walnut dose is shown in
Table 1[28]. Subjects' clinical characteristics and nutrient
status at randomization are presented in Table 2. No sig-
nificant changes in body weight were observed during
either intervention. Baseline dietary intake data is pre-
sented in Table 3. Data from subsequent food frequency
questionnaires revealed no significant differences in sub-
jects' dietary intake within or between each intervention
phase.
The main study outcomes are presented in Table 4.
After 6 wk, the magnitude of change in plasma ORAC,
ORAC-pca, and FRAP levels was higher with 42 g/d wal-
nuts than with 21 g/d, while the degree of lipid peroxida-
tion, assessed by MDA production, was lower. Although
no significant within- or between-group changes were
observed for any of these antioxidant activity measures
(including TAP), the proportional changes in ORAC and
MDA with each walnut dose were consistent with a dose-
response effect. Compared to the number of subjects who
responded to the low dose, a higher proportion of sub-
jects responded with an increase in plasma ORAC,
ORAC-pca, and FRAP following the higher walnut dose.
The percent of subjects with increased antioxidant activ-
ity after 6 wk with 42 vs. 21 g/d was 71 vs. 48% for ORAC,
67 vs. 43% for ORAC-pca, and 38 vs. 19% for FRAP,
respectively.
Following 6 wk of daily walnut consumption, the
changes in plasma total thiols and other antioxidant bio-
markers, including total phenols and GPX, were not sig-
nificant for either dose (Table 4). However, compared to
fasting levels, plasma total thiols were elevated within 1 h
of walnut consumption with both walnut doses during
the baseline and end visits for each intervention phase
(Fig 1). No improvements in other measures assessed
within 1 h of consumption (total phenols, ORAC, ORAC-
pca or FRAP) were observed (data not shown), except for
a 3.1% increase in total phenols within 1 h of walnut con-
sumption during the baseline visit for the 42 g dose (P =
0.063 compared with fasting plasma levels).
Changes in plasma micronutrient status are presented
in Table 5. No significant within- or between-group
changes were observed with respect to the antioxidant
nutrients, i.e., total carotenoids, tocopherols, and vitamin
C. Adjusting the changes in antioxidant activity mea-
sures, i.e., ORAC, ORAC-pca, FRAP, TAP, and MDA for
changes in plasma total carotenoids, α- and γ-tocopherol,
and vitamin C had no effect on these outcomes. Although
the changes in plasma folate and magnesium were pro-
Table 1: Major nutrients present in walnuts1
Quantity per dose
Nutrient 21 g 42 g
Calories (kcal) 139 278
Total fat (g) 14 28
Fatty acids, 18:2 (g) 8.6 17.1
Fatty acids, 18:3 (g) 2 4.1
α-Tocopherol (mg) 0.2 0.3
γ-Tocopherol (mg) 4.4 8.9
Vitamin B6 (mg) 0.1 0.2
Folate (μg) 21 42
Magnesium (mg) 34 67
1Adapted from [28]
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icant within- or between-group differences were
observed for either of these nutrients. The magnitude of
change in plasma PLP levels after 6 wk was similar with
both doses, i.e., 19.0% with 21 g/d and 16.2% with 42 g/d.
However, only the change attained with the higher dose
was statistically significant compared to the baseline PLP
level for this intervention (P = 0.045).
RBC linoleic and linolenic acids were increased after 6
wk with both walnut doses (Fig 2). Compared to baseline
levels, the magnitude of change in linoleic acid was signif-
icant after 6 wk with 42 g/d. Interestingly, plasma total
cholesterol, LDL, and triglyceride levels decreased signif-
icantly compared to baseline levels after 6 wk with the 21
g/d dose, but not with the higher dose (Table 6).
Discussion
Our study is consistent with the results reported by Davis
et al. [11] that chronic walnut consumption has little
effect on antioxidant capacity in humans when measured
with ORAC, and extends the list of null data to include
ORAC-pca, FRAP, and TAP. ORAC-pca measures the
inhibitory capacity of small hydrophilic antioxidant mole-
cules alone against free radicals, i.e., absent the contribu-
tion of plasma proteins, while FRAP measures the ferric
reducing ability of antioxidant compounds present in
plasma. The TAP assay assesses the activities of both
lipophilic and hydrophilic antioxidants when radicals are
formed in hydrophobic cell compartments. The increased
linoleic and linolenic acid content confirmed dietary
compliance. Despite the observed increase in RBC PUFA
associated with walnut consumption, this substrate for
lipid peroxidation only minimally affected MDA and
antioxidant capacity.
The in vivo antioxidant activity of walnuts in this and
other studies may be reflected by the protection of sus-
ceptible substrates against free radical attack. Thus, while
the shift to more PUFA in the diet and plasma with wal-
nut consumption could be predicted to increase plasma
biomarkers of lipid peroxidation, we found no change in
MDA. The absence of an increase in MDA may be a
result of the concurrent intake and bioavailability of wal-
nut phytochemicals, including phenolic compounds and
γ-tocopherol. Anderson et al. [6] demonstrated that wal-
nut polyphenols inhibit AAPH-mediated oxidation of
plasma and LDL and spare endogenous LDL α-tocoph-
erol, in vitro. A reduction or null effect of walnut con-
sumption on lipid peroxidation is consistent with the
findings of other human intervention studies. For exam-
ple, Zambon et al. [29] found that 41-56 g/d of walnuts
Table 2: Subject characteristics at baseline1,2
Dose at randomization
21 g 42 g
Age, y 64.8 ± 7.8 56.6 ± 13.9
BMI, kg/m2 27.3 ± 3.6 27.4 ± 3.8
Female, % (n) 55 (6) 60 (6)
Male, % (n) 45 (5) 40 (4)
Systolic BP, mm Hg 109 ± 7 116 ± 14
Diastolic BP, mm Hg 73 ± 10 72 ± 10
TC, mmol/L 5.49 ± 1.17 5.54 ± 1.06
LDL, mmol/L 3.37 ± 0.96 3.50 ± 0.91
HDL, mmol/L 1.61 ± 0.44 1.48 ± 0.18
Triglycerides, mmol/L 1.21 ± 0.40 1.24 ± 0.53
Total carotenoids, μmol/L 2.2 ± 1.0 2.6 ± 1.2
α-tocopherol, μmol/L 26.4 ± 6.8 29.3 ± 7.1
γ-tocopherol, μmol/L 5.4 ± 3.1 4.4 ± 2.7
Vitamin C, μmol/L 48.3 ± 21.0 60.8 ± 30.1
Folate, nmol/L 56.0 ± 17.2 50.1 ± 17.4
PLP, nmol/L 44.6 ± 17.7 67.8 ± 59.7
1No significant between-group differences were detected using the independent samples t-test (continuous variables) or chi-square test 
(categorical variables).
2Values are means ± SD or n (%)
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LDL α-tocopherol or on the resistance of LDL against
Cu2+-induced oxidation, when compared with a control
diet. Similarly, Ros et al. [30] found an increase in γ-
tocopherol with the consumption of 40-65 g/d walnuts
for 4 wk, but no change in either the lag time of LDL oxi-
dation, MDA production or on number of oxidatively
modified LDL particles when compared with a control
diet. Haddad et al. [31] showed a small, but significant
increase in γ-tocopherol and decrease in MDA, but no
significant change in FRAP or TEAC after 4 wk with 67 g/
d of pecans.
Although chronic walnut consumption in this pilot
study may not have a readily apparent and marked impact
on antioxidant capacity in healthy older adults, its acute
postprandial action to increase plasma total thiols is
noteworthy. Interestingly, Jenkins et al. [32] observed an
increase in plasma total thiols following the consumption
of a meal containing almonds in contrast to decreases in
this element of antioxidant defenses after meals contain-
ing bread, rice, or potatoes. These findings suggest that
nuts may reduce postprandial oxidative damage to pro-
teins. Postprandial increases in biomarkers of oxidative
damage and decreased antioxidant defenses (including
SH groups) have been reported in both diabetic and
healthy subjects [33]. This evidence suggests that epi-
sodic postprandial increases in oxidative stress may con-
tribute to the pathogenesis and complications of several
Table 3: Subjects' baseline daily dietary intake1,2
Dose at randomization
Nutrient 21 g 42 g
Energy (kcal) 1638 ± 440 1466 ± 458
Protein (g) 77 ± 35 77 ± 33
Carbohydrate (g) 177 ± 57 168 ± 41
Fat (g) 68 ± 26 54 ± 26
Cholesterol (mg) 294 ± 209 328 ± 262
Fiber (g) 13 ± 5 14 ± 6
Thiamin (mg) 1.3 ± 0.4 1.2 ± 0.4
Riboflavin (mg) 2.1 ± 1.2 2.0 ± 0.6
Niacin (mg) 18 ± 5 18 ± 6
Folate (μg) 254 ± 100 308 ± 116
Vitamin B6 (mg) 1.7 ± 0.6 1.7 ± 0.4
Vitamin B12 (mg) 6.1 ± 3.1 7.3 ± 4.5
Vitamin C (mg) 92 ± 56 115 ± 43
Retinol (μg) 538 ± 356 574 ± 381
β-carotene (μg) 2056 ± 1175 3232 ± 1712
Total tocopherols (mg) 7.0 ± 1.9 7.8 ± 3.6
α-tocopherol (mg) 5.7 ± 1.8 6.6 ± 3.4
γ-tocopherol (mg) 12.7 ± 6.1 10.9 ± 8.0
Vitamin D (μg) 7.8 ± 5.8 6.3 ± 2.9
Calcium (mg) 1011 ± 658 964 ± 415
Magnesium (mg) 284 ± 98 281 ± 77
Potassium (mg) 2826 ± 1028 2970 ± 805
Sodium (mg) 2697 ± 910 2705 ± 1068
Iron (mg) 12 ± 4 13 ± 5
Zinc (mg) 12 ± 5 12 ± 5
Selenium (μg) 100 ± 36 102 ± 58
1No significant between-group differences were detected using the independent samples t-test (continuous variables).
2Values are means ± SD
McKay et al. Nutrition Journal 2010, 9:21
http://www.nutritionj.com/content/9/1/21
Page 7 of 10chronic diseases. Indeed, Ashfaq et al. [34] have reported
a direct correlation between thiol biomarkers of oxidative
stress and atherosclerosis risk in healthy adults, indepen-
dent of traditional risk factors and inflammation.
The increase in RBC linoleic and linolenic acids we
observed with walnut consumption is consistent with the
findings of Rajaram et al. [35] who fed subjects a daily
dose of 1.50 oz (42 g)/2400 kcal for 6 wk. However, their
study employed a controlled feeding protocol in which all
other n-3 fatty acid-rich foods (including fatty fish) were
excluded during the walnut intervention. Subjects in our
study were not instructed to limit their consumption of
these particular foods, so the magnitude of change we
expected with the addition of walnuts alone was lower.
Despite this attenuated response, our study more accu-
rately reflects the effects of incorporating walnuts into
the diet of the general population. In addition, baseline
linoleic acid levels in our subjects were similar to the lev-
els achieved by subjects in the Rajaram study [35] follow-
ing the 6 wk walnut diet, while our baseline linolenic acid
levels were more than double their post-intervention lev-
els. The higher baseline nutritional status of our subjects
likely also contributed to their smaller change in magni-
tude. The lack of a significant change in plasma γ-tocoph-
erol following walnut consumption may be due to the
continuing use of corn and soybean oils among the sub-
jects. Interestingly, PLP increased with both walnut doses
in this study, despite no reported increase in protein con-
sumption from either animal or vegetable sources.
There are several limitations to this pilot study, includ-
ing its small sample size, the absence of a placebo group,
and lack of control over subjects' background diet during
the intervention. The sufficiency of nutrient intake and
status in our population may have also affected the main
Table 4: Changes in antioxidant activity following 6 wk intervention with daily walnut consumption1
Walnut intervention dose
21 g/d 42 g/d











ORAC 2.3 ± 16.4 0.534 5.6 ± 15.5 0.115 0.435
ORAC-pca -2.1 ± 29.6 0.752 8.2 ± 29.4 0.218 0.322
FRAP -3.1 ± 10.6 0.197 -0.8 ± 12.1 0.768 0.503
TAP 0.9 ± 6.8 0.572 -0.7 ± 9.7 0.745 0.505
Lipid peroxidation biomarker:
MDA 8.2 ± 40.6 0.367 2.1 ± 27.9 0.734 0.522
Antioxidant status:
Total phenols -2.0 ± 7.0 0.202 -2.0 ± 5.9 0.135 0.995
Total thiols -2.2 ± 13.2 0.476 1.8 ± 32.2 0.813 0.680
GPX -1.3 ± 7.8 0.452 -2.4 ± 7.5 0.164 0.646
1Values are means ± SD
Figure 1 Acute changes in plasma total thiols within 1 h of walnut 
consumption. Mean total plasma thiols just prior to consuming a sin-
gle 21 g dose were 2.90 ± 0.52 and 2.81 ± 0.41 mM, respectively, during 
the start and end of intervention visits for this phase. Mean total plas-
ma thiols just prior to a single 42 g dose were 2.65 ± 0.63 and 2.55 ± 
0.38 mM during the start and end visits for this phase. Changes in plas-
ma total thiols were measured 1 h following walnut consumption, and 
compared with the respective baseline values at each visit using paired 
t-tests. P > 0.05 for between group differences, * P < 0.05 for change 
from baseline values, **P = 0.058 for change from baseline.
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plasma nutrient concentrations and measures of antioxi-
dant capacity in subjects who are already well-nourished.
Although increases in oxidative stress status and reduc-
tions in antioxidant capacity are associated with advanc-
ing age, the quality of the subjects' habitual diet may have
reduced our ability to detect changes in these outcomes
with the addition of walnuts alone. Nonetheless, this
study largely confirms earlier observations of the effect of
walnuts in human studies and extends our knowledge of
their putative role in health maintenance and disease pre-
vention.
Conclusions
Walnut consumption did not significantly change the
plasma antioxidant capacity of healthy, well-nourished
older adults in this pilot study. However, improvements
in linoleic acid and pyridoxal phosphate were observed
with chronic consumption, while total plasma thiols were
enhanced acutely. Future studies investigating the antiox-
idant effects of walnuts in humans are warranted, but
should include either a larger sample size or a controlled
feeding intervention.
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